CuriRx Launches CuriLytics Platform

Publication
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter, October 2021
Volume 16
Issue 10

CuriRx’s CuriLytics platform is a mass spectrometry instrument that will support complex biotherapeutics development.

CuriRx, a contract research and product development organization, announced the launch of their CuriLytics platform on Sept. 21, 2021. The CuriLytics platform is designed to support the development of complex biotherapeutics.

CuriLytics uses high-resolution mass spectrometry and various orthogonal characterization methods to characterize modern biopharmaceutical drugs. This allows it to identify quality attributes of protein candidates at the individual residue level. It can analyze complex molecules such as recombinant proteins, monoclonal antibodies, or antibody drug conjugates, among others.

"Analytical methods to characterize and assess highly complex biotherapeutics have struggled to keep up, putting many drug-development programs at risk,” said CuriRx CEO Indu Javeri in a company press release. “The CuriLytics platform is designed to provide confidence to biotherapeutic developers from discovery to regulatory approval."

Source: CuriRX

Recent Videos
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content